VXRT
Vaxart, Inc.
Key Financials
Net Income
$16.3M
↑ 124.4%
Revenue
$237.3M
↑ 726.7%
Operating Income
$18.1M
↑ 127.3%
Total Liabilities
$98.3M
↓ 8.5%
EPS (Diluted)
$0.07
↑ 121.2%
Total Assets
$186.1M
↑ 11.8%
Cash & Equivalents
$34.8M
↓ 21.0%
Shareholders' Equity
$87.8M
↑ 49.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/17/2026 | View on SEC |
| S-3 | 4/16/2026 | View on SEC |
| 4 | 3/31/2026 | View on SEC |
| 4 | 3/31/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VXRT |
| Company Name | Vaxart, Inc. |
| CIK | 72444 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 550-3500 |